J

Johnson & Johnson

Makes prescription drugs and medical devices

TransCend Process Release Lead for Intercompany Accounting

Full-TimePosted on 10/20/2026Deadline 12/1/26
No salary listed
Mid, Senior
Bachelor's
Taguig, Metro Manila, Philippines+2 moreMore locations: Suzhou, Jiangsu, China | Bengaluru, Karnataka, India
In Person
Project & Program ManagementProject Management

About the job

Requirements
  • Five to eight years of job experience in Finance, preferably in the MedTech sector.
  • A Bachelor's degree in Accounting, Finance, or a similar subject.
  • A professional accountancy qualification.
  • Fluency in English.
  • Experience working with IA application.
  • Knowledge of US GAAP, SAP, and Intercompany Accounting; S4 HANA is preferred.
  • Ability to write documentation, including process flows, DTPs, and work instructions.
  • Leadership skills to lead and manage a team with a defined area of responsibility.
  • Ability to communicate orally and in writing with end users and project teams.
  • Ability to drive consensus and resolve conflicts across multiple parties with conflicting views.
  • Ability to champion the design solution and frame changes in a way that engages the end-user community.
  • Ability to assess business readiness for successful transition based on test feedback.
  • Ability to plan and coordinate multiple and complex activities.
  • Understanding of J&J finance processes.
  • Strong project management, transition, and knowledge transfer skills.
Responsibilities
  • Represent user requirements for design and prioritize requirements for the respective process within the region.
  • Support Solution Confirmation (Fit/Gap assessment) for the process against the Global Template.
  • Support Release Leads in delivering concurrent deployments within the region.
  • Recruit, lead, and coach Implementation CoE Analysts for the respective process within the region.
  • Coordinate testing (BST, UAT, and BRT) across the respective process within the region.
  • Execute testing at all stages (BST, UAT, BRT, and Hypercare) as needed, including testing SOX controls as needed.
  • Collaborate with other workstreams to support end-to-end testing within the region.
  • Manage defects and incidents during testing and Hypercare.
  • Lead data cleansing, conversion, and migration efforts for the region across production and quality environments.
  • Participate in Change Impact Assessment.
  • Oversee documentation updates for the respective process within the region.
  • Participate in production cutover planning and execution within the region.
  • Support stage gates, including metrics, within the region.
  • Act as a change agent and super user for service delivery teams within the region.
  • Proactively share process improvement and automation ideas.
  • Work with required stakeholders to ensure proper and timely communications.
  • Ensure a smooth transition to the new operating model with minimal operational disruption.
  • Ensure overall customer satisfaction during deployment.
  • Resolve and escalate issues and risks to management as required.
  • Engage key stakeholders and lead change management efforts to ensure a smooth transition to new ways of working.
Desired Qualifications
  • Finance experience in the MedTech sector.
  • S4 HANA knowledge.
  • Experience in Finance Transformation (technology and process).
  • Understanding of the GS Finance organization or environment.
  • Skills listed as preferred include budgeting, budget management, business alignment, developing others, expense controls, financial analysis, financial competence, financial forecasting, financial reports, financial risk management, financial statement analysis, inclusive leadership, leadership, process optimization, relationship building, succession planning, team management, and vendor management.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.